Compare
Cocrystal Pharma, Inc. vs FibroBiologics, Inc. vs Can-Fite BioPharma Ltd. vs Soligenix, Inc.
| Latest fiscal year | Cocrystal Pharma, Inc. COCP | FibroBiologics, Inc. FBLG | Can-Fite BioPharma Ltd. CANF | Soligenix, Inc. SNGX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $405.0K | n/a |
| Revenue growth (YoY) | n/a | n/a | -39.9% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$8.83M | -$18.65M | -$9.83M | -$11.08M |
| EPS (Diluted) | -$0.78 | -$0.42 | -$5.97 | -$2.14 |
| Operating cash flow | -$8.19M | -$16.39M | -$8.95M | -$10.27M |
| Free cash flow | -$8.20M | -$16.66M | -$8.95M | -$10.27M |
| Cash & equivalents | $7.03M | $4.89M | $5.53M | n/a |
| Total assets | $9.71M | $9.62M | $9.51M | $9.24M |
| Total liabilities | $3.38M | $3.46M | n/a | $3.94M |
| Shareholders' equity | $6.33M | $6.16M | $5.59M | $5.29M |
| Return on year-end equity | -139.5% | -302.9% | -175.8% | -209.4% |
| Shares outstanding | 13.78M | n/a | 2.62M | 10.09M |
Revenue, most recent five fiscal years
| Fiscal year | Cocrystal Pharma, Inc. | FibroBiologics, Inc. | Can-Fite BioPharma Ltd. | Soligenix, Inc. |
|---|---|---|---|---|
| Latest | $2.01M Ended 2020-12-31 | n/a | $405.0K Ended 2025-12-31 | $119.4K Ended 2024-12-31 |
| 1 year earlier | $6.56M Ended 2019-12-31 | n/a | $674.0K Ended 2024-12-31 | $839.4K Ended 2023-12-31 |
| 2 years earlier | n/a | n/a | $743.0K Ended 2023-12-31 | $948.9K Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $810.0K Ended 2022-12-31 | $824.3K Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $853.0K Ended 2021-12-31 | $2.36M Ended 2020-12-31 |